利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.021 秒)

    CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection
    1.
    发明申请
    CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection 有权
    CC趋化因子受体5 DNA，新型动物模型和HIV感染治疗剂

    公开(公告)号：US20050118677A1

    公开(公告)日：2005-06-02

    申请号：US10846185

    申请日：2004-05-14

    申请人： Christophe Combadiere ,  Philip Murphy

    发明人： Christophe Combadiere ,  Philip Murphy

    IPC分类号： A61K38/00 ,  C07K14/715 ,  C12N15/12 ,  A61K38/17 ,  C07H21/04 ,  C07K14/74

    CPC分类号： C07K14/7158 ,  A01K2217/05 ,  A61K38/00

    摘要： The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCRS plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

    摘要翻译： 人类巨噬细胞对人类免疫缺陷病毒（HIV）感染的易感性取决于人CD4分子和CC细胞因子受体5的细胞表面表达。CCR5是G蛋白偶联细胞表面分子的7-跨膜段超家族的成员。 CCRS在一些HIV分离株的感染膜融合步骤中发挥重要作用。 建立稳定的非人细胞系和具有共表达人CD4和CCR5的细胞的转基因哺乳动物为继续研究艾滋病毒感染提供了宝贵的工具。 此外，结合CCR5，CCR5变体和CCR5结合剂的能够阻断HIV和靶细胞之间的膜融合的抗体代表了HIV巨噬细胞趋化株的潜在的抗HIV治疗剂。

    CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection
    2.
    发明申请
    CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection 有权
    CC趋化因子受体5 DNA，新型动物模型和HIV感染治疗剂

    公开(公告)号：US20070087990A1

    公开(公告)日：2007-04-19

    申请号：US11594375

    申请日：2006-11-07

    申请人： Christophe Combadiere ,  Yu Feng ,  Ghalib Alkhatib ,  Edward Berger ,  Philip Murphy ,  Christopher Broder ,  Paul Kennedy

    发明人： Christophe Combadiere ,  Yu Feng ,  Ghalib Alkhatib ,  Edward Berger ,  Philip Murphy ,  Christopher Broder ,  Paul Kennedy

    IPC分类号： A61K31/70 ,  C12P21/06 ,  A01N43/04

    CPC分类号： C07K14/7158 ,  A01K2217/05 ,  A61K38/00

    摘要： The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

    摘要翻译： 人类巨噬细胞对人类免疫缺陷病毒（HIV）感染的易感性取决于人CD4分子和CC细胞因子受体5的细胞表面表达。CCR5是G蛋白偶联细胞表面分子的7-跨膜段超家族的成员。 CCR5在一些HIV分离物感染的膜融合步骤中起着重要作用。 建立稳定的非人细胞系和具有共表达人CD4和CCR5的细胞的转基因哺乳动物为继续研究艾滋病毒感染提供了宝贵的工具。 此外，结合CCR5，CCR5变体和CCR5结合剂的能够阻断HIV和靶细胞之间的膜融合的抗体代表了HIV巨噬细胞趋化株的潜在的抗HIV治疗剂。

    CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION
    3.
    发明申请
    CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION 审中-公开
    CC CHEMOKINE RECEPTOR 5 DNA，新动物模型和艾滋病毒感染治疗剂

    公开(公告)号：US20110117101A1

    公开(公告)日：2011-05-19

    申请号：US13012482

    申请日：2011-01-24

    申请人： Christophe Combadiere ,  Philip M. Murphy ,  Edward A. Berger

    发明人： Christophe Combadiere ,  Philip M. Murphy ,  Edward A. Berger

    IPC分类号： A61K39/395 ,  A61P31/18 ,  C12N5/071

    CPC分类号： C07K14/7158 ,  A01K2217/05 ,  A61K38/00

    摘要： The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

    摘要翻译： 人类巨噬细胞对人类免疫缺陷病毒（HIV）感染的易感性取决于人CD4分子和CC细胞因子受体5的细胞表面表达。CCR5是G蛋白偶联细胞表面分子的7-跨膜段超家族的成员。 CCR5在一些HIV分离物感染的膜融合步骤中起着重要作用。 建立稳定的非人细胞系和具有共表达人CD4和CCR5的细胞的转基因哺乳动物为继续研究艾滋病毒感染提供了宝贵的工具。 此外，结合CCR5，CCR5变体和CCR5结合剂的能够阻断HIV和靶细胞之间的膜融合的抗体代表了HIV巨噬细胞趋化株的潜在的抗HIV治疗剂。

    CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection
    5.
    发明授权
    CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection 有权
    CC趋化因子受体5 DNA，新型动物模型和HIV感染治疗剂

    公开(公告)号：US08198042B2

    公开(公告)日：2012-06-12

    申请号：US10846185

    申请日：2004-05-14

    申请人： Christophe Combadiere ,  Philip M. Murphy

    发明人： Christophe Combadiere ,  Philip M. Murphy

    IPC分类号： C12N15/12 ,  C07K14/705

    CPC分类号： C07K14/7158 ,  A01K2217/05 ,  A61K38/00

    摘要： The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

    摘要翻译： 人类巨噬细胞对人类免疫缺陷病毒（HIV）感染的易感性取决于人CD4分子和CC细胞因子受体5的细胞表面表达。CCR5是G蛋白偶联细胞表面分子的7-跨膜段超家族的成员。 CCR5在一些HIV分离物感染的膜融合步骤中起着重要作用。 建立稳定的非人细胞系和具有共表达人CD4和CCR5的细胞的转基因哺乳动物为继续研究艾滋病毒感染提供了宝贵的工具。 此外，结合CCR5，CCR5变体和CCR5结合剂的能够阻断HIV和靶细胞之间的膜融合的抗体代表了HIV巨噬细胞趋化株的潜在的抗HIV治疗剂。

    CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection
    8.
    发明授权
    CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection 有权
    CC趋化因子受体5 DNA，新型动物模型和HIV感染治疗剂

    公开(公告)号：US07374872B2

    公开(公告)日：2008-05-20

    申请号：US11594375

    申请日：2006-11-07

    申请人： Christophe Combadiere ,  Philip M. Murphy

    发明人： Christophe Combadiere ,  Philip M. Murphy

    IPC分类号： C12Q1/00

    CPC分类号： C07K14/7158 ,  A01K2217/05 ,  A61K38/00

    摘要： The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

    摘要翻译： 人类巨噬细胞对人类免疫缺陷病毒（HIV）感染的易感性取决于人CD4分子和CC细胞因子受体5的细胞表面表达。CCR5是G蛋白偶联细胞表面分子的7-跨膜段超家族的成员。 CCR5在一些HIV分离物感染的膜融合步骤中起着重要作用。 建立稳定的非人细胞系和具有共表达人CD4和CCR5的细胞的转基因哺乳动物为继续研究艾滋病毒感染提供了宝贵的工具。 此外，结合CCR5，CCR5变体和CCR5结合剂的能够阻断HIV和靶细胞之间的膜融合的抗体代表了HIV巨噬细胞趋化株的潜在的抗HIV治疗剂。